- Home
- MOLN vs KRRO Comparison
MOLN vs KRRO Comparison
Compare MOLN & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- KRRO
- Stock Information
- Founded
- MOLN 2004
- KRRO 2014
- Country
- MOLN Switzerland
- KRRO United States
- Employees
- MOLN N/A
- KRRO N/A
- Industry
- MOLN
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- KRRO Health Care
- Exchange
- MOLN Nasdaq
- KRRO Nasdaq
- Market Cap
- MOLN 142.6M
- KRRO 125.4M
- IPO Year
- MOLN 2021
- KRRO 2019
- Fundamental
- Price
- MOLN $3.53
- KRRO $13.85
- Analyst Decision
- MOLN
- KRRO Strong Buy
- Analyst Count
- MOLN 0
- KRRO 7
- Target Price
- MOLN N/A
- KRRO $85.67
- AVG Volume (30 Days)
- MOLN 1.2K
- KRRO 126.6K
- Earning Date
- MOLN 08-25-2025
- KRRO 08-12-2025
- Dividend Yield
- MOLN N/A
- KRRO N/A
- EPS Growth
- MOLN N/A
- KRRO N/A
- EPS
- MOLN N/A
- KRRO N/A
- Revenue
- MOLN $2,525,030.00
- KRRO $4,821,000.00
- Revenue This Year
- MOLN N/A
- KRRO $65.08
- Revenue Next Year
- MOLN $1,000.00
- KRRO N/A
- P/E Ratio
- MOLN N/A
- KRRO N/A
- Revenue Growth
- MOLN N/A
- KRRO N/A
- 52 Week Low
- MOLN $3.36
- KRRO $10.29
- 52 Week High
- MOLN $9.79
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- MOLN 41.49
- KRRO 47.77
- Support Level
- MOLN $3.65
- KRRO $14.75
- Resistance Level
- MOLN $3.96
- KRRO $16.77
- Average True Range (ATR)
- MOLN 0.09
- KRRO 1.47
- MACD
- MOLN -0.01
- KRRO 0.03
- Stochastic Oscillator
- MOLN 20.33
- KRRO 25.23
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.